Well at least we know why the CDC and FDA aren't reporting on the safety signals coming out of VAERS!

Or do we?

I do a lot of interviews about my ongoing VAERS work that commenced at the onset of the roll-out of the COVID-19 injectable products. More often than not, the interviewer will ask me why the owners of the VAERS data, namely the CDC and the FDA, are not raising the alarm on the many safety signals being thrown off by VAERS. From Creutzfeldt-Jacob Disease to Myocarditis, there are no regular and formal reports brought to the attention of the public, and in fact, in the case of the latter, the problem is minimized and the public subsequently patronized.

Well, in lieu of doing proper causality assessments or reporting on Proportional Reporting Ratio (PRR)¹, which is a calculation that anyone can do on a napkin, or even Empirical Bayesian (EB) data mining, they have done nothing. Well, at least not that we have been allowed to know about. Admittedly so.

Question: What if the injuries being reported by the millions are actually caused by the COVID-19 injectable products? What if even a fraction of them are?

I guess the CDC would have some serious egg on their face, hmm? I guess that would be a good reason not to fess up to any existing data or assessments that demonstrate causal links, hmm? But you know what I think? I think you STILL MUST tell the bloody truth.

Every single human being needs to know 2 things:

1. Medical doctors (yes, those same ones you go to for medical advice) typically follow CDC guidelines - STRICTLY

2. The CDC are NOT doing due diligence regarding pharmacovigilance assessments in the context of the COVID-19 injectable products.

   1. no PRR calculations

   2. no causality assessments (Head to Understanding ‘Vaccine’ Causation Conference - WCH)

   3. no EB analyses

Thought you should know.

1. Rose, J. 2021, Critical Appraisal of VAERS Pharmacovigilance: Is
the U.S. Vaccine Adverse Events Reporting System (VAERS) a Functioning Pharmacovigilance System? Science, Public Health Policy & the Law
Volume 3:100–129.